[Receptor agonists and antagonists: the present and future].
Tanaka
H
H
School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D018680:Cholinergic Antagonists; D020109:Devazepide; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D008024:Ligands; D019808:Losartan; D010455:Peptides; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D011964:Receptors, Gastrointestinal Hormone / Q000037:antagonists & inhibitors*; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors*; D013777:Tetrazoles / Q000494:pharmacology*
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001570:Benzodiazepinones; D001713:Biphenyl Compounds; D018680:Cholinergic Antagonists; D007093:Imidazoles; D008024:Ligands; D010455:Peptides; D011949:Receptors, Cholecystokinin; D011964:Receptors, Gastrointestinal Hormone; D018013:Receptors, Neuropeptide; D013777:Tetrazoles; C050802:motilin receptor; D004917:Erythromycin; C061752:EM 523; D020109:Devazepide; D019808:Losartan; C077793:candesartan cilexetil